Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|HER2-Negative Breast Carcinoma
Interventions: DRUG: Cyclophosphamide|DRUG: Docetaxel|OTHER: Medical Chart Review|OTHER: Questionnaire Administration
Sponsor: City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)